Jodie Morrison - Akebia Ther Director
| AKBA Stock | USD 1.26 0.06 4.55% |
Director
Ms. Jodie P. Morrison is Director of the Company. Ms. Morrison has served as a member of our Board of Directors since completion of the Merger in December 2018. She had served on the Board of Directors of Keryx from June 2016 until completion of the Merger and as Interim Chief Executive Officer of Keryx from April 2018 until completion of the Merger. Since February 2019, she was the Chief Executive Officer of Cadent Therapeutics, Inc., a company developing therapies for patients with movement and neurological disorders. She served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for prostate cancer and other hormonally driven diseases, from March 2013 until May 2017 and served on its Board of Directors from March 2013 until June 2018. From December 2006 until March 2013, Ms. Morrison held other senior positions with Tokai, including Chief Operating Officer, Head of Clinical Affairs and Program Operations and Vice President of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison served as Director of Clinical Operations and Medical Affairs at Dyax Corporationrationration, or Dyax. Prior to joining Dyax, Ms. Morrison held clinical management positions at both Curis, Inc. and at Diacrin, Inc. Ms. Morrison currently serves on the Boards of Directors of Cadent Therapeutics, Inc. and Aileron Therapeutics, Inc. since 2018.
| Age | 42 |
| Tenure | 6 years |
| Address | 245 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 871 2098 |
| Web | https://www.akebia.com |
Akebia Ther Management Efficiency
The company has return on total asset (ROA) of (0.0931) % which means that it has lost $0.0931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5345) %, meaning that it created substantial loss on money invested by shareholders. Akebia Ther's management efficiency ratios could be used to measure how well Akebia Ther manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.78, whereas Return On Tangible Assets are forecasted to decline to (0.37). At present, Akebia Ther's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 182 M, whereas Other Current Assets are forecasted to decline to about 12.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kurt Graves | Seres Therapeutics | 50 | |
| Theodore Schroeder | Cidara Therapeutics | 63 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Daniel Burgess | Cidara Therapeutics | 56 | |
| Philip Vickers | AVROBIO | 58 | |
| Ian Clark | AVROBIO | 57 | |
| Thomas Adams | Hepion Pharmaceuticals | 74 | |
| Lorence Kim | Seres Therapeutics | 43 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Phillip Donenberg | AVROBIO | 57 | |
| Timothy Block | Hepion Pharmaceuticals | 61 | |
| Chrysa Mineo | Cidara Therapeutics | 52 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Aharon Schwartz | Protalix Biotherapeutics | 74 | |
| Yodfat Buchris | Protalix Biotherapeutics | 44 | |
| David McGirr | X4 Pharmaceuticals | 63 | |
| Arnold Lippa | Hepion Pharmaceuticals | 70 | |
| Christopher Paige | AVROBIO | 64 | |
| David Berry | Seres Therapeutics | 37 | |
| Roger Kornberg | Protalix Biotherapeutics | 68 | |
| MD FACP | Hepion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.0931 |
Akebia Ther Leadership Team
Elected by the shareholders, the Akebia Ther's board of directors comprises two types of representatives: Akebia Ther inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akebia. The board's role is to monitor Akebia Ther's management team and ensure that shareholders' interests are well served. Akebia Ther's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akebia Ther's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Burke, Senior Vice President Chief Medical Officer | ||
| Dell Faulkingham, Senior Vice President Chief Commercial Officer | ||
| Teresa Compton, Chief Scientific Officer and Sr. VP | ||
| Tamara Dillon, VP of HR | ||
| Ramin FarzanehFar, Vice President - Medical Research | ||
| Ronald Renaud, Director | ||
| Michael Heffernan, Director | ||
| Nicole JD, Chief VP | ||
| Jason Amello, CFO, Sr. VP and Treasurer | ||
| Carolyn Rucci, Senior Counsel | ||
| Kimberly Garko, Senior Officer | ||
| Michael Rogers, Director | ||
| John MBA, President, CEO | ||
| Steven MD, Senior Officer | ||
| Muneer Satter, Independent Chairman of the Board | ||
| Rita Jain, Senior Vice President Chief Medical Officer | ||
| CGMA CPA, CFO VP | ||
| Brad Maroni, Senior Vice President Chief Medical Officer | ||
| John Rice, Chairman of the Board | ||
| Scott Canute, Director | ||
| Jodie Morrison, Director | ||
| Mercedes Carrasco, Director Communications | ||
| Duane Nash, Independent Director | ||
| David Spellman, CFO VP | ||
| Tracey Vetterick, Vice Administration | ||
| Nicole Hadas, Sr. VP, General Counsel and Secretary | ||
| Michael Wyzga, Independent Director | ||
| Thierry Bilbault, VP Devel | ||
| Theresa McNeely, Senior Vice President Corporate Communications & Investor Relations | ||
| Kristie Bolieau, VP Controller | ||
| Steven Gilman, Director | ||
| Michel Dahan, Senior Vice President and Chief Business Officer | ||
| Michael Clayman, Director | ||
| Karen Tubridy, Senior Vice President Chief Development Officer | ||
| Douglas MBA, Vice Strategy | ||
| Mark Rosch, Vice President - Regulatory Affairs | ||
| Bradley Maroni, Senior Vice President Chief Medical Officer | ||
| Nicholas Grund, Senior Officer | ||
| Cynthia Smith, Director | ||
| Maxine Gowen, Director | ||
| Ed Joyce, Vice President - Investor Relations and Corporate Communications | ||
| Meredith Bowman, Senior Officer | ||
| Richard Malabre, Chief Officer | ||
| Mark Enyedy, Director | ||
| John Butler, CEO and President and Director | ||
| Violetta Cotreau, Chief VP | ||
| Adrian Adams, Independent Chairman of the Board |
Akebia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akebia Ther a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.0931 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 337.63 M | ||||
| Shares Outstanding | 209.37 M | ||||
| Shares Owned By Insiders | 1.93 % | ||||
| Shares Owned By Institutions | 26.62 % | ||||
| Number Of Shares Shorted | 13.69 M | ||||
| Price To Earning | (4.84) X |
Pair Trading with Akebia Ther
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akebia Ther position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akebia Ther will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Akebia Ther could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akebia Ther when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akebia Ther - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akebia Ther to buy it.
The correlation of Akebia Ther is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akebia Ther moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akebia Ther moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akebia Ther can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.Note that the Akebia Ther information on this page should be used as a complementary analysis to other Akebia Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Akebia Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.28) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.007 | Return On Assets (0.09) | Return On Equity (5.53) |
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.